



Agile Therapeutics Completes Enrollment in Phase 3 NEW CHOICE Study of AG200-15, Agile’s Novel, Low-Dose Weekly Contraceptive Patch

Rapid Completion of Enrollment Speaks to Patient Desire for More Convenient Contraceptive Options

PRINCETON, N.J. – October 4, 2010 --Agile Therapeutics, Inc., a pharmaceutical development company specializing in women’s healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile’s lead contraceptive patch. Agile’s NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive. The NEW CHOICE Study completed enrollment two months ahead of schedule, enabling Agile to plan for an earlier submission of the New Drug Application (NDA) for AG200-15 to the U.S. Food and Drug Administration (FDA).

Dr. Thomas Rossi, Agile’s President and CEO, commented, “We are very pleased to complete enrollment in the NEW CHOICE Study ahead of schedule. The rapid enrollment rate, 1500 women in eight weeks, reflects a broad interest amongst contraceptive users for the convenience of a once weekly contraceptive patch. We look forward to the continued progress of AG200-15 and anticipate the expedited timeline will enable us to file for FDA approval earlier than previously anticipated.”

Dr. Marie Foegh, Chief Medical Officer and Vice President, Clinical Research and Development of Agile Therapeutics, stated, “Physicians perceive a large need among their patients for the comfort and convenience of Agile’s low-dose, weekly contraceptive patch, and we are very pleased to potentially make our patch available earlier than anticipated. We extend a special thanks to the investigators of the study. Without their commitment to and support of the study, we would not have been able to complete enrollment in two months.” Agile is working with DSP Clinical Research to manage the NEW CHOICE Study.

About Agile's Low-Dose Contraceptive Patch (AG200-15)

AG200-15 is an innovative, low-dose, weekly contraceptive patch, which offers a new advancement in the women's healthcare market. As a convenient, low-dose alternative to oral contraceptives, the patch will fill an unmet need, so women will not have to take a pill every day. Phase 2 clinical study results have shown AG200-15 met its primary endpoints of ovulation suppression, cycle control and safety. In addition, a definitive pharmacokinetic (PK) study demonstrated Agile's patch delivered a dose of EE comparable to that found in low-dose, oral contraceptives. The PK study results will be presented by Dr. David Archer at the upcoming annual meeting of the American Society for Reproductive Medicine in October 2010.

About Agile Therapeutics, Inc.

Agile Therapeutics is a pharmaceutical development company specializing in women's healthcare products, with an initial focus on developing safer, more convenient methods of hormonal contraception. In addition to Agile's lead, advanced-stage program to develop AG200-15, the Company also is developing a low-dose, progestin-only contraceptive patch, AG900. Both AG200-15 and AG900 incorporate Agile's proprietary SKINFUSION™ technology, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit <http://www.agiletherapeutics.com>.

Contact:

Burns McClellan on behalf of Agile Therapeutics

Justin Jackson, 212-213-0006

jjackson@burnsmc.com